| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Department of Chemistry and Biochemistry and 2 Office of Information Technology, University of Texas at Arlington; 3 Texas Cancer Center, Arlington, Texas; 4 Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia; Departments of 5 Pathology and 6 Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston, Galveston, Texas; and 7 Lexicon Genetics, Inc., The Woodlands, Texas
Requests for reprints: Sanjay Awasthi, Department of Chemistry and Biochemistry, University of Texas at Arlington, Science Hall Room 223, 502 Yates Street, Arlington, TX 76019-0065. Phone: 817-272-5444; Fax: 817-272-3808; E-mail: sanjay.awasthi{at}usoncology.com.
RLIP76 (RALBP1) is a glutathione-conjugate transporter that is a critical component of clathrin-coated pitmediated endocytosis, as well as in stress responses. In cultured cells, it provides protection from stressors including heat, oxidant chemicals, chemotherapeutic agents, UV irradiation, and X-irradiation. Here, we show marked reduction in glutathione conjugate transport capacity and stepwise increase in radiation sensitivity associated with heterozygous or homozygous loss of the RLIP76 gene in mice. Survival after radiation in homozygous knockout animals was significantly shorter than either the heterozygous knockouts or the wild type. Delivery of recombinant RLIP76 to mice lacking RLIP76 via a liposomal delivery system rescued radiation sensitivity. Furthermore, treatment of wild-type mice with RLIP76-containing liposomes conferred resistance to radiation. These findings suggest that inhibiting RLIP76 could be used for sensitization to radiation during cancer therapy and that RLIP76 liposomes could be radioprotective agents useful for treatment of iatrogenic or catastrophic radiation poisoning.
This article has been cited by other articles:
![]() |
S. S. Singhal, J. Singhal, S. Yadav, M. Sahu, Y. C. Awasthi, and S. Awasthi RLIP76: A Target for Kidney Cancer Therapy Cancer Res., May 15, 2009; 69(10): 4244 - 4251. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Awasthi, S. S. Singhal, Y. C. Awasthi, B. Martin, J.-H. Woo, C. C. Cunningham, and A. E. Frankel RLIP76 and Cancer Clin. Cancer Res., July 15, 2008; 14(14): 4372 - 4377. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Singhal, S. Yadav, K. Drake, J. Singhal, and S. Awasthi Hsf-1 and POB1 Induce Drug Sensitivity and Apoptosis by Inhibiting Ralbp1 J. Biol. Chem., July 11, 2008; 283(28): 19714 - 19729. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Margutti, P. Matarrese, F. Conti, T. Colasanti, F. Delunardo, A. Capozzi, T. Garofalo, E. Profumo, R. Rigano, A. Siracusano, et al. Autoantibodies to the C-terminal subunit of RLIP76 induce oxidative stress and endothelial cell apoptosis in immune-mediated vascular diseases and atherosclerosis Blood, May 1, 2008; 111(9): 4559 - 4570. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Singhal, J. Singhal, S. Yadav, S. Dwivedi, P. J. Boor, Y. C. Awasthi, and S. Awasthi Regression of Lung and Colon Cancer Xenografts by Depleting or Inhibiting RLIP76 (Ral-Binding Protein 1) Cancer Res., May 1, 2007; 67(9): 4382 - 4389. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Singhal, Y. C. Awasthi, and S. Awasthi Regression of Melanoma in a Murine Model by RLIP76 Depletion Cancer Res., February 15, 2006; 66(4): 2354 - 2360. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |